- Home
- AGNCM vs PHVS Comparison
AGNCM vs PHVS Comparison
Compare AGNCM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGNCM
- PHVS
- Stock Information
- Founded
- AGNCM 2008
- PHVS 2015
- Country
- AGNCM United States
- PHVS Switzerland
- Employees
- AGNCM N/A
- PHVS N/A
- Industry
- AGNCM Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AGNCM Real Estate
- PHVS Health Care
- Exchange
- AGNCM Nasdaq
- PHVS Nasdaq
- Market Cap
- AGNCM N/A
- PHVS 1.3B
- IPO Year
- AGNCM N/A
- PHVS 2021
- Fundamental
- Price
- AGNCM $25.01
- PHVS $23.38
- Analyst Decision
- AGNCM
- PHVS Strong Buy
- Analyst Count
- AGNCM 0
- PHVS 5
- Target Price
- AGNCM N/A
- PHVS $35.60
- AVG Volume (30 Days)
- AGNCM 15.2K
- PHVS 123.8K
- Earning Date
- AGNCM 10-20-2025
- PHVS 11-12-2025
- Dividend Yield
- AGNCM 9.10%
- PHVS N/A
- EPS Growth
- AGNCM N/A
- PHVS N/A
- EPS
- AGNCM 0.26
- PHVS N/A
- Revenue
- AGNCM $496,000,000.00
- PHVS N/A
- Revenue This Year
- AGNCM $9.87
- PHVS N/A
- Revenue Next Year
- AGNCM $58.56
- PHVS N/A
- P/E Ratio
- AGNCM $44.94
- PHVS N/A
- Revenue Growth
- AGNCM N/A
- PHVS N/A
- 52 Week Low
- AGNCM $23.01
- PHVS $11.51
- 52 Week High
- AGNCM $25.63
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AGNCM 44.13
- PHVS 55.19
- Support Level
- AGNCM $24.99
- PHVS $23.20
- Resistance Level
- AGNCM $25.14
- PHVS $24.83
- Average True Range (ATR)
- AGNCM 0.10
- PHVS 1.34
- MACD
- AGNCM -0.02
- PHVS -0.02
- Stochastic Oscillator
- AGNCM 9.65
- PHVS 58.45
About AGNCM AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.